Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2006

NDRI Receives Funding Commitment for Rare Disease Initiative

  • Genzyme presented the National Disease Research Interchange (NDRI) with the first of a five-year installment to support the growth and development of NDRI's National Rare Disease Biomaterials Resource. The check of $50,000 will go toward NDRI’s effort to increase the supply of donated human tissues and donor DNA and cell lines for studying rare diseases.

    More than 6,000 orphan diseases, those with an incidence in the U.S. of less than 200,000 cases per year, have been identified. NDRI's pilot program on this initiative served some 90 scientists in more than 100 rare diseases. NDRI's current tissue catalogue contains disease-relevant frozen specimens from rare diseases, including ALS, amyloidosis, Batten disease, DiGeorge syndrome, Huntington's disease, Lewy body dementia, Marfan syndrome, muscular dystrophy, lupus, progressive supranuclear palsy, and sarcoidosis.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »